Loading...
•
Dec 31, 2024
Alnylam Q4 2024 Earnings Report
Key Takeaways
Alnylam Pharmaceuticals reported strong revenue growth in Q4 2024, driven by the continued success of AMVUTTRA. The company significantly reduced its net loss YoY while maintaining strong product revenue momentum.
Revenue by Segment
Forward Guidance
Alnylam expects strong growth in 2025, with product revenues projected between $2.05B and $2.25B, and aims for non-GAAP profitability.
Positive Outlook
- Projected revenue growth of 25-37% YoY.
- Strong demand for AMVUTTRA continues to drive sales.
- Regulatory decision on Vutrisiran for ATTR-CM expected in March 2025.
- Expected milestone payments from Roche collaboration.
- Increased R&D pipeline with over 25 programs in development.
Challenges Ahead
- Continued net losses despite revenue growth.
- High SG&A and R&D expenses impacting profitability.
- Regulatory risks associated with pipeline approvals.
- Potential market competition in RNAi therapeutics.
- Foreign exchange fluctuations may impact revenue growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...